AU2013356793A1 - Application of maltotriose-coated 4th generation polypropyleneimine dendrimer PPI-G4-OS-Mal-III - Google Patents

Application of maltotriose-coated 4th generation polypropyleneimine dendrimer PPI-G4-OS-Mal-III Download PDF

Info

Publication number
AU2013356793A1
AU2013356793A1 AU2013356793A AU2013356793A AU2013356793A1 AU 2013356793 A1 AU2013356793 A1 AU 2013356793A1 AU 2013356793 A AU2013356793 A AU 2013356793A AU 2013356793 A AU2013356793 A AU 2013356793A AU 2013356793 A1 AU2013356793 A1 AU 2013356793A1
Authority
AU
Australia
Prior art keywords
ppi
mal
iii
dendrimer
maltotriose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013356793A
Other languages
English (en)
Inventor
Dietmar Appelhans
Maria BRYSZEWSKA
Ida FRANIAK-PIETRYGA
Barbara Klajnert-Maculewicz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Łódź
Original Assignee
LODZKI, University of
University of Łódź
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LODZKI, University of, University of Łódź filed Critical LODZKI, University of
Publication of AU2013356793A1 publication Critical patent/AU2013356793A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers
    • C08G83/004—After treatment of dendrimers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2013356793A 2012-12-06 2013-12-06 Application of maltotriose-coated 4th generation polypropyleneimine dendrimer PPI-G4-OS-Mal-III Abandoned AU2013356793A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PL401936A PL234888B1 (pl) 2012-12-06 2012-12-06 Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-OS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej
PLP-401936 2012-12-06
PCT/PL2013/000163 WO2014088435A1 (en) 2012-12-06 2013-12-06 Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-os-mal-iii

Publications (1)

Publication Number Publication Date
AU2013356793A1 true AU2013356793A1 (en) 2015-07-23

Family

ID=49955472

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013356793A Abandoned AU2013356793A1 (en) 2012-12-06 2013-12-06 Application of maltotriose-coated 4th generation polypropyleneimine dendrimer PPI-G4-OS-Mal-III

Country Status (9)

Country Link
US (1) US9877985B2 (cg-RX-API-DMAC10.html)
EP (1) EP2928479A1 (cg-RX-API-DMAC10.html)
JP (1) JP2016501261A (cg-RX-API-DMAC10.html)
KR (1) KR20150093216A (cg-RX-API-DMAC10.html)
AU (1) AU2013356793A1 (cg-RX-API-DMAC10.html)
CA (1) CA2893973A1 (cg-RX-API-DMAC10.html)
IL (1) IL239144A0 (cg-RX-API-DMAC10.html)
PL (1) PL234888B1 (cg-RX-API-DMAC10.html)
WO (1) WO2014088435A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL234887B1 (pl) * 2012-12-06 2020-04-30 Univ Lodzki Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-DS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej
PL416636A1 (pl) * 2016-03-24 2017-09-25 Univ Łódzki Medyczne zastosowanie dendrymeru polipropylenoiminowego czwartej generacji, opłaszczonego maltotriozą

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090208580A1 (en) 2005-09-19 2009-08-20 Regents Of The University Of Michigan Functionalized dendrimer-encapsulated and dendrimer-stabilized nanoparticles
US20110177602A1 (en) * 2007-06-27 2011-07-21 Endress + Hauser Conducts Gesellschaft furMess-und Regeltechnik mbH +Co. KG Composite Structure
PL234887B1 (pl) * 2012-12-06 2020-04-30 Univ Lodzki Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-DS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej

Also Published As

Publication number Publication date
KR20150093216A (ko) 2015-08-17
PL234888B1 (pl) 2020-04-30
CA2893973A1 (en) 2014-06-12
WO2014088435A1 (en) 2014-06-12
PL401936A1 (pl) 2014-06-09
US20150306134A1 (en) 2015-10-29
EP2928479A1 (en) 2015-10-14
US9877985B2 (en) 2018-01-30
JP2016501261A (ja) 2016-01-18
IL239144A0 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
Shang et al. Platelet-membrane-camouflaged black phosphorus quantum dots enhance anticancer effect mediated by apoptosis and autophagy
Leanza et al. Direct pharmacological targeting of a mitochondrial ion channel selectively kills tumor cells in vivo
Zou et al. Piperlongumine as a direct TrxR1 inhibitor with suppressive activity against gastric cancer
Ma et al. Reversing drug resistance of soft tumor-repopulating cells by tumor cell-derived chemotherapeutic microparticles
Gutierrez et al. A new pyridazinone exhibits potent cytotoxicity on human cancer cells via apoptosis and poly-ubiquitinated protein accumulation
Martínez-Torres et al. Chitosan gold nanoparticles induce different ROS-dependent cell death modalities in leukemic cells
Yih et al. Arsenite induces prominent mitotic arrest via inhibition of G 2 checkpoint activation in CGL-2 cells
Mameri et al. Oxidative stress as an underlying mechanism of anticancer drugs cytotoxicity on human red blood cells' membrane
Hussain et al. Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium
Zhang et al. Hypoxia-triggered tumor specific glutamine inhibition for reversing cisplatin resistance of chemotherapy
Albuz et al. Effects of B2O3 (boron trioxide) on colon cancer cells: our first-step experience and in vitro results
Nie et al. Selenium speciation-dependent cancer radiosensitization by induction of G2/M cell cycle arrest and apoptosis
Szwed et al. Doxorubicin–transferrin conjugate triggers pro-oxidative disorders in solid tumor cells
Knotigova et al. Application of advanced microscopic methods to study the interaction of carboxylated fluorescent nanodiamonds with membrane structures in THP-1 cells: activation of inflammasome NLRP3 as the result of lysosome destabilization
Chen et al. An organic free radical generator independent on hydrogen peroxide for chemodynamic and immunotherapy in vivo
US9877985B2 (en) Application of maltotriose-coated 4th generation polypropyleneimine dendrimer PPI-G4-OS-MAL-III
Zhang et al. Voltage-dependent anion channels influence cytotoxicity of ME-344, a therapeutic isoflavone
Guo et al. Inhibition of autophagy in hepatocarcinoma cells promotes chemotherapeutic agent-induced apoptosis during nutrient deprivation
US20150320692A1 (en) Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-ds-mal-iii
US10022395B2 (en) Application of maltotriose-coated 4th generation poly(propyleneimine) dendrimer PPI-G4-OS-Mal-III
Zhang et al. Cancer cell membrane fused liposomal platinum (iv) prodrugs overcome cisplatin resistance in esophageal squamous cell carcinoma chemotherapy
Wang et al. The discovery of acyl thiourea derivatives as potent hydrophobic tagging degraders targeting SIRT2 for the treatment of ovarian cancer
WO2020171138A1 (ja) 放射線治療による抗腫瘍免疫効果を評価する末梢血バイオマーカー
Chen et al. Deguelin blocks cells survival signal pathways and induces apoptosis of HL-60 cells in vitro
Nikolić et al. New O-alkyl chalcone derivative exhibits antiproliferative potential in colorectal and cervical cancer cells by inducing G0/G1 cell cycle arrest and mitochondrial-mediated apoptosis

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ FRANIAK-PIETRYGA, IDA; BRYSZEWSKA, MARIA; APPELHANS, DIETMAR AND KLAJNERT-MACULEWICZ, BARBARA

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted